Clinical trial · Observational
Treatment After Palbociclib-containing Regimens
A Multi-center Study of the Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on Palbociclib in HR+/HER2- Metastatic Breast Cancer
NCT04517318CI-TRIAL-00053046completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- PFS
- timeFrame
- 6 weeks
- description
- Progression free survival
- measure
- Adverse events
- timeFrame
- 6 weeks
- description
- Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. woman, age \> 18 years old 2. Diagnosed with HR+/HER2- Metastatic Breast Cancer 3. Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy 4. Complete medical history was available Exclusion Criteria: 1\. Medical history was incomplete
References
Publications (1)
- DERIVEDLi Y, Li W, Gong C, Zheng Y, Ouyang Q, Xie N, Qu Q, Ge R, Wang B. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer. Ther Adv Med Oncol. 2021 Jun 11;13:17588359211022890. doi: 10.1177/17588359211022890. eCollection 2021. PMID 34178122